HCVS
MCID: HMN038
MIFTS: 30

Human Coronavirus Sensitivity (HCVS)

Categories: Infectious diseases

Aliases & Classifications for Human Coronavirus Sensitivity

MalaCards integrated aliases for Human Coronavirus Sensitivity:

Name: Human Coronavirus Sensitivity 57 13
Coronavirus 229e Susceptibility; Cvs 57
Coronavirus 229e Susceptibility 57
Hcvs 57
Cvs 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant (15q11-q12)


HPO:

31
human coronavirus sensitivity:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM® 57 122460
MedGen 41 C1852539
SNOMED-CT via HPO 68 263681008

Summaries for Human Coronavirus Sensitivity

MalaCards based summary : Human Coronavirus Sensitivity, also known as coronavirus 229e susceptibility; cvs, is related to cyclic vomiting syndrome and trisomy 2 mosaicism. An important gene associated with Human Coronavirus Sensitivity is HCVS (Human Coronavirus Sensitivity). The drugs Pentoxifylline and Methadone have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and bone, and related phenotype is susceptibility to coronavirus 229e.

More information from OMIM: 122460

Related Diseases for Human Coronavirus Sensitivity

Diseases in the Human Coronavirus Sensitivity family:

Coronavirus Infectious Disease

Diseases related to Human Coronavirus Sensitivity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Related Disease Score Top Affiliating Genes
1 cyclic vomiting syndrome 11.7
2 trisomy 2 mosaicism 11.0
3 neu-laxova syndrome 1 10.9
4 anophthalmos with limb anomalies 10.9
5 rabies 10.5
6 chromosomal triplication 10.5
7 down syndrome 10.3
8 turner syndrome 10.1
9 47,xyy 10.1
10 migraine with or without aura 1 10.0
11 spinal muscular atrophy 10.0
12 vascular disease 10.0
13 muscular atrophy 10.0
14 reversible cerebral vasoconstriction syndrome 10.0
15 mosaic trisomy 3 10.0
16 orofaciodigital syndrome viii 9.9
17 ataxia and polyneuropathy, adult-onset 9.9
18 pallister-killian syndrome 9.9
19 omphalocele 9.9
20 patau syndrome 9.9
21 muscular dystrophy 9.9
22 48,xyyy 9.9
23 mosaic trisomy 13 9.9
24 tetraploidy 9.9
25 thalassemia 9.9
26 autosomal trisomy 9.9
27 mosaic monosomy x 9.9
28 hypoglossia-hypodactylia 9.8
29 amyotrophic lateral sclerosis 1 9.8
30 poland syndrome 9.8
31 prader-willi syndrome 9.8
32 neural tube defects 9.8
33 anus, imperforate 9.8
34 cystic fibrosis 9.8
35 jejunal atresia 9.8
36 oeis complex 9.8
37 hypomelanosis of ito 9.8
38 muscular dystrophy, duchenne type 9.8
39 glycine encephalopathy 9.8
40 beta-thalassemia 9.8
41 pulmonary hypertension 9.8
42 atrial fibrillation 9.8
43 porencephaly 9.8
44 human cytomegalovirus infection 9.8
45 pre-eclampsia 9.8
46 microcephaly 9.8
47 hydronephrosis 9.8
48 coronary thrombosis 9.8
49 oligohydramnios 9.8
50 impotence 9.8

Graphical network of the top 20 diseases related to Human Coronavirus Sensitivity:



Diseases related to Human Coronavirus Sensitivity

Symptoms & Phenotypes for Human Coronavirus Sensitivity

Human phenotypes related to Human Coronavirus Sensitivity:

31
# Description HPO Frequency HPO Source Accession
1 susceptibility to coronavirus 229e 31 HP:0005396

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Immunology:
susceptibility to coronavirus 229e

Clinical features from OMIM®:

122460 (Updated 05-Apr-2021)

Drugs & Therapeutics for Human Coronavirus Sensitivity

Drugs for Human Coronavirus Sensitivity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
2
Methadone Approved Phase 4 76-99-3 4095
3
Ethanol Approved Phase 4 64-17-5 702
4
Fosamprenavir Approved Phase 4 226700-79-4 131536
5
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
6
Mycophenolic acid Approved Phase 4 24280-93-1 446541
7
Zidovudine Approved Phase 4 30516-87-1 35370
8
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
9
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
12
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
13
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616
14
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
15
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
16
Lactulose Approved Phase 4 4618-18-2 11333
17
Promethazine Approved, Investigational Phase 4 60-87-7 4927
18
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
19
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
20
Interferon alfacon-1 Approved, Investigational Phase 4 118390-30-0 9554198
21
Nelfinavir Approved Phase 4 159989-64-7 64143
22
Baclofen Approved Phase 4 1134-47-0 2284
23
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
24
Cobicistat Approved Phase 4 1004316-88-4
25
Ezetimibe Approved Phase 4 163222-33-1 150311
26
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
27
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
28
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
29
Nevirapine Approved Phase 4 129618-40-2 4463
30
Lopinavir Approved Phase 4 192725-17-0 92727
31
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
32
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
34
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
35
Heroin Phase 4 5462328
36 Detox adjuvant Phase 4
37 Vasodilator Agents Phase 4
38 Radiation-Protective Agents Phase 4
39 Anticholesteremic Agents Phase 4
40 Hypolipidemic Agents Phase 4
41 Neurotransmitter Agents Phase 4
42 Anesthetics Phase 4
43 Hypnotics and Sedatives Phase 4
44 Hepatitis C Antibodies Phase 4
45 Narcotics Phase 4
46 Narcotic Antagonists Phase 4
47 Analgesics Phase 4
48 Anti-Inflammatory Agents Phase 4
49 Anti-Bacterial Agents Phase 4
50 Lamivudine, zidovudine drug combination Phase 4

Interventional clinical trials:

(show top 50) (show all 993)
# Name Status NCT ID Phase Drugs
1 Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney Unknown status NCT03296930 Phase 4 Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
2 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care Unknown status NCT03364725 Phase 4 Glecaprevir-pibrentasvir
3 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
4 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
5 An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
6 Curing HCV in Incarcerated Patients Unknown status NCT03018353 Phase 4 Patients receiving Sof/Vel (Epclusa) and Navigation services
7 Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02745132 Phase 4
8 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination Therapy in Treatment of Chronic Hepatitis C Infection in Egyptian Children With Gaucher Disease Unknown status NCT03721627 Phase 4 Ledipasvir/Sofosbuvir
9 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
10 A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Unknown status NCT03003338 Phase 4 OBV/PTV/r and DSV;Placebo to match OBV/PTV/r and DSV
11 An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Unknown status NCT02950870 Phase 4 Ombitasvir-Paritaprevir-Ritonavir;Dasabuvir;Ribavirin
12 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
13 The Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4 Unknown status NCT03743727 Phase 4 Combined therapy LDV and SOF
14 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
15 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
16 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
17 Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
18 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
19 Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4 Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
20 A Randomized, Multicenter, Open Label Study Evaluating the Efficacy and Safety of Tailored Regimens With Peginterferon Alfa-2a Plus Ribavirin According Viral Kinetics for Genotype 1 Chronic Hepatitis C Patients Completed NCT01937728 Phase 4 A: Peg-interferon alpha-2a & Ribavirin;B: Peg-interferon alpha-2a & Ribavirin;C: Peg-interferon alpha-2a & Ribavirin;D: Peg-interferon alpha-2a & Ribavirin;E: Peg-interferon alpha-2a & Ribavirin;F: Peg-interferon alpha-2a & Ribavirin
21 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
22 THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders Completed NCT02786537 Phase 4 sofosbuvir/ledipasvir;ombitasvir/paritaprevir/ritonavir (Phase 1 only);elbasvir/grazoprevir;Dasabuvir;Ribavirin
23 Efficacy of Low Dose Pegylated Interferon-α 2a Plus Ribavirin for the Treatment of Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients. Completed NCT00553930 Phase 4 Pegylated interferon alfa-2a and Ribavirin;Pegylated interferon alfa 2a and Ribavirin
24 A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant Completed NCT02945150 Phase 4 elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
25 A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV Completed NCT02128542 Phase 4 Sofosbuvir;RBV
26 Evaluation of Liver Fibrosis by Serum Hyalornic Acid Measurement in β-Thalassemic Children Infected With Hepatitis C Virus Before and After Direct-Acting Antiviral Therapy Completed NCT03961828 Phase 4 Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
27 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria. JAILFREE-C Completed NCT02768961 Phase 4 sofosbuvir;ledipasvir
28 Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program Completed NCT01405027 Phase 4
29 deLIVER: Direct Acting Antiviral Effects on the Liver Completed NCT02938013 Phase 4 Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX];Sofosbuvir/Velpatasvir (SOF/VEL)
30 Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, Vietnam Completed NCT03537196 Phase 4 Sofosbuvir 400 mg and Daclatasvir 60 mg;Sofosbuvir 400 mg and Daclatasvir 90 mg;Ribavirin;Sofosbuvir and Daclatasvir for 24 weeks
31 The Immunologic Effects of HCV Therapy With Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs. Completed NCT02347345 Phase 4 Harvoni (Fixed dose combination ledipasvir/sofosbuvir)
32 PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver Completed NCT03619837 Phase 4 Sofosbuvir/Velpatasvir;Sofosbuvir/Velpatasvir/Voxilaprevir
33 A Randomized-Controlled, Comparative Study, To Evaluate the Efficacy of Tailored Regimen of Peginterferon Alfa Plus Ribavirin According to Rapid Virological Response and Baseline Viral Loads in the Treatment of Patients With Chronic Hepatitis C/Hepatitis B Co-Infection: A Pilot Study (Pioneer) Completed NCT02339337 Phase 4
34 Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication Completed NCT00152581 Phase 4 Pegylated interferon-alfa2a (Pegasys); ribavirin
35 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
36 A Phase IV Pilot Study to Assess Community-Based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia Completed NCT02339038 Phase 4 Ledipasvir 90 mg and Sofosbuvir 400 mg
37 An Open-Label, Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus (HCV) Infection Genotype 2K/1B- NINJA Study Completed NCT03050905 Phase 4 VEKIRAX;EXVIERA
38 A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects With Chronic Hepatitis C Virus (HCV) Genotype 4 Infection Completed NCT03111108 Phase 4 EBR/GZR (50 mg/100 mg) FDC
39 Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Egyptian Patients With HCV Completed NCT03069001 Phase 4 Sofosbuvir-Simeprevir;Sofosbuvir-Ribavirin
40 A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent. Completed NCT00866021 Phase 4 Lopinavir/ritonavir;Lopinavir/ritonavir with two nucleoside analogs
41 Improvement of the Surveillance and Control of Liver Disease and Complication Due to Chronic Hepatitis C: Project A) Antiviral Drugs Use, Efficacy, Safety and Costs; Project B) Kinetics of Virological Response. Completed NCT01195181 Phase 4 peginterferon plus ribavirin
42 Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin HCV Therapy on Insulin Resistance and Lipid Profile Completed NCT02734173 Phase 4 ABT450r-ABT267-ABT333 +/- Ribavirin
43 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
44 Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs Completed NCT03133065 Phase 4 treatment of HCV with oral direct acting antiviral therapy
45 Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon (Hepatitis Eradication Accuracy Trial of Sofosbuvir): An Observational Non-interventional Real Life Trial Completed NCT02804386 Phase 4 Sofosbuvir
46 Safety and Tolerability of Ribavirin (RO 20-9963) in Combination With Peginterferon Alfa-2a (40 kD)in Patients With Chronic Hepatitis C Completed NCT00922779 Phase 4 peginterferon alfa-2a [Pegasys];ribavirin
47 Effect of High Dose vs. Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3, High Viral Load Without Rapid Virological Response Completed NCT00830609 Phase 4 Peginterferon alfa 2 A;Peginterferon alfa 2 A, ribavirin + Epo Beta;ribavirin;ribavirin;Peginterferon alfa 2;ribavirin
48 A Single-center Pilot Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Heart Transplant Recipients With Post-transplant Treatment of Hepatitis C Viremia With Mavyret Completed NCT03382847 Phase 4
49 Educate, Test and Treat Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages Completed NCT04177043 Phase 4 DAAs
50 A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C Completed NCT02881762 Phase 4 Maraviroc

Search NIH Clinical Center for Human Coronavirus Sensitivity

Genetic Tests for Human Coronavirus Sensitivity

Anatomical Context for Human Coronavirus Sensitivity

MalaCards organs/tissues related to Human Coronavirus Sensitivity:

40
Liver, Kidney, Bone, Whole Blood, T Cells, Bone Marrow, Thyroid

Publications for Human Coronavirus Sensitivity

Articles related to Human Coronavirus Sensitivity:

(show top 50) (show all 87)
# Title Authors PMID Year
1
Coronavirus 229E susceptibility in man-mouse hybrids is located on human chromosome 15. 61 57
6285532 1982
2
Survivors Achieving Stable Housing: Implementation, Challenges, and Lessons Learned. 61
33479750 2021
3
Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study. 61
32910431 2020
4
Cooling efficiency of vests with different cooling concepts over 8-hour trials. 61
33222661 2020
5
Measuring intradialyser transmembrane and hydrostatic pressures: pitfalls and relevance in haemodialysis and haemodiafiltration. 61
32905251 2020
6
Cognitive/Functional Measures Predict Alzheimer's Disease, Dependent on Hippocampal Volume. 61
30668830 2020
7
Clinical utility of structural connectomics in predicting memory in temporal lobe epilepsy. 61
32358221 2020
8
A systematic review on high conservation value assessment (HCVs): Challenges and framework for future research on conservation strategy. 61
31884271 2020
9
High resolution vehicular PM10 emissions over megacity Delhi: Relative contributions of exhaust and non-exhaust sources. 61
31683208 2020
10
Healthcare trajectory of children with rare bone disease attending pediatric emergency departments. 61
31900214 2020
11
Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. 61
31337501 2020
12
A comprehensive comparison and analysis of soil screening values derived and used in China and the UK. 61
31735398 2020
13
An efficient utilization of high chromium vanadium slag: Extraction of vanadium based on manganese carbonate roasting and detoxification processing of chromium-containing tailings. 61
31202069 2019
14
Exploring the relationship of hyaluronic acid molecular weight and active targeting efficiency for designing hyaluronic acid-modified nanoparticles. 61
32104479 2019
15
Hepatitis C virus sequence divergence preserves p7 viroporin structural and dynamic features. 61
31182749 2019
16
Hippocampal shape alterations in healthy young women with familial risk for unipolar depression. 61
29367060 2018
17
Assessment of GHG mitigation and CDM technology in urban transport sector of Chandigarh, India. 61
29039038 2018
18
Patient's behaviors and missed opportunities for vaccination against seasonal epidemic influenza and evaluation of their impact on patient's influenza vaccine uptake. 61
29565990 2018
19
Renal function affects hippocampal volume and cognition: The role of vascular burden and amyloid deposition. 61
28224692 2017
20
Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus. 61
28864074 2017
21
Late-Life Depression, Hippocampal Volumes, and Hypothalamic-Pituitary-Adrenal Axis Regulation: A Systematic Review and Meta-analysis. 61
28318491 2017
22
Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems. 61
28322919 2017
23
Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. 61
27927921 2017
24
The epithelial-mesenchymal transition (EMT) is regulated by oncoviruses in cancer. 61
27279361 2016
25
Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing. 61
26953209 2016
26
[The efficiency of antiviral therapy in patients with chronic -hepatitis C infected with hepatitis C virus recombinants]. 61
27489903 2016
27
The human hippocampus is not sexually-dimorphic: Meta-analysis of structural MRI volumes. 61
26334947 2016
28
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus. 61
26415801 2015
29
Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging. 61
26104935 2015
30
Taking high conservation value from forests to freshwaters. 61
25948151 2015
31
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. 61
25099344 2015
32
Decreased right hippocampal volumes and neuroprogression markers in adolescents with bipolar disorder. 61
25925781 2015
33
Robustness of automated hippocampal volumetry across magnetic resonance field strengths and repeat images. 61
24985688 2014
34
Hypoxia-inducible factor 1 and its role in viral carcinogenesis. 61
24698149 2014
35
A small-molecule inhibitor of hepatitis C virus infectivity. 61
24165192 2014
36
Genetic characterization of hepatitis C virus in long-term RNA replication using Li23 cell culture systems. 61
24625789 2014
37
Vehicular emission inventory of criteria pollutants in Delhi. 61
23741649 2013
38
The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. 61
23880821 2013
39
MR Volumetry of Hippocampus in Normal Adult Malay of Age 50 Years Old and Above. 61
24043993 2013
40
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. 61
22264648 2012
41
Two methods of heterokaryon formation to discover HCV restriction factors. 61
22825033 2012
42
Hippocampal volume in children with temporal lobe epilepsy compared to healthy children: a magnetic resonance imaging study. 61
22406776 2012
43
Prevalence and risk factors of asymptomatic hepatitis C virus infection in bangladesh. 61
25755305 2011
44
Genetic variability and diversity of intracellular genome-length hepatitis C virus RNA in long-term cell culture. 61
19082684 2009
45
HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A. 61
19779801 2009
46
[Replication of hepatitis C virus genome]. 61
19374197 2008
47
Hepatitis C virus coinfection and superinfection. 61
17230411 2007
48
Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. 61
17255316 2007
49
Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5' untranslated regions. 61
16957039 2006
50
Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. 61
16840336 2006

Variations for Human Coronavirus Sensitivity

Expression for Human Coronavirus Sensitivity

Search GEO for disease gene expression data for Human Coronavirus Sensitivity.

Pathways for Human Coronavirus Sensitivity

GO Terms for Human Coronavirus Sensitivity

Sources for Human Coronavirus Sensitivity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....